Bin Ma, Upendra A Argikar, Luying Chen, Lionel Cheruzel, Sungjoon Cho, Ting-Jia Gu, Simon Hauri, Valerie M Kramlinger, Xiuli Li, Joyce Liu, Simone Schadt, Herana Kamal Seneviratne, Rachel Liuqing Shi, Lloyd Wei Tat Tang, Donglu Zhang, Guo Zhong, S Cyrus Khojasteh
{"title":"Metabolism of new drug modalities research advances - 2024 year in review.","authors":"Bin Ma, Upendra A Argikar, Luying Chen, Lionel Cheruzel, Sungjoon Cho, Ting-Jia Gu, Simon Hauri, Valerie M Kramlinger, Xiuli Li, Joyce Liu, Simone Schadt, Herana Kamal Seneviratne, Rachel Liuqing Shi, Lloyd Wei Tat Tang, Donglu Zhang, Guo Zhong, S Cyrus Khojasteh","doi":"10.1080/03602532.2025.2542220","DOIUrl":null,"url":null,"abstract":"<p><p>New drug modalities (NDMs) have gained significant popularity and attention in recent years due to their ability to target previously undruggable pathways and offer new strategies for tackling complex diseases. This trend is reflected in our review, which encompasses 17 publications, an increase from 11 last year and includes a growing number of contributors across industry and academia. We have focused on five categories of NDMs: (1) Peptides with an emphasis on macrocyclic structures; (2) Bivalent protein degraders, also known as proteolysis-targeting chimeras (PROTACs); (3) Conjugated drugs, including peptide-drug and antibody-drug conjugates; (4) Antisense oligonucleotides and <i>N</i>-acetylgalactosamine (GalNAc) conjugated oligonucleotides; and (5) Covalent inhibitors.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"1-38"},"PeriodicalIF":3.8000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Metabolism Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03602532.2025.2542220","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
New drug modalities (NDMs) have gained significant popularity and attention in recent years due to their ability to target previously undruggable pathways and offer new strategies for tackling complex diseases. This trend is reflected in our review, which encompasses 17 publications, an increase from 11 last year and includes a growing number of contributors across industry and academia. We have focused on five categories of NDMs: (1) Peptides with an emphasis on macrocyclic structures; (2) Bivalent protein degraders, also known as proteolysis-targeting chimeras (PROTACs); (3) Conjugated drugs, including peptide-drug and antibody-drug conjugates; (4) Antisense oligonucleotides and N-acetylgalactosamine (GalNAc) conjugated oligonucleotides; and (5) Covalent inhibitors.
期刊介绍：
Drug Metabolism Reviews consistently provides critically needed reviews of an impressive array of drug metabolism research-covering established, new, and potential drugs; environmentally toxic chemicals; absorption; metabolism and excretion; and enzymology of all living species. Additionally, the journal offers new hypotheses of interest to diverse groups of medical professionals including pharmacologists, toxicologists, chemists, microbiologists, pharmacokineticists, immunologists, mass spectroscopists, as well as enzymologists working in xenobiotic biotransformation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
